Alopecia areata during treatment with biologic agents.
Tosti
Antonella
A
Pazzaglia
Massimiliano
M
Starace
Michela
M
Bellavista
Sara
S
Vincenzi
Colombina
C
Tonelli
Gabriella
G
D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002464:Cell Migration Inhibition; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; C472181:efalizumab